Lonza Prices CHF 235 Million Dual Tranche Straight Bonds

Basel, Switzerland, 13 June 2017 - Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel ("Lonza"), today announced the pricing of its dual tranche CHF 235 million straight bonds. The bonds have a maturity of 4 and 7 years respectively with coupons of 0.200% and 0.700%.

The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for the refinancing of the Capsugel acquisition.

Key Data

Issue Size 4-Year Bond: CHF 125 million

Expected Payment Date: 12 July 2017

Maturity: 12 July 2021 (4 years)

Issue Price: 100.179 percent

Redemption Price: 100 percent

Coupon: 0.200 percent p.a.

Joint Lead Managers: BNP Paribas (Suisse) AG, Credit Suisse AG,
UBS AG and Zürcher
Kantonalbank

Issue Size 7-Year Bond: CHF 110 million

Expected Payment Date: 12 July 2017

Maturity: 12 July 2024 (7 years)

Issue Price: 100.222 percent

Redemption Price: 100 percent

Coupon: 0.700 percent p.a.

Joint Lead Managers: BNP Paribas (Suisse) AG, Credit Suisse AG,
UBS AG and Zürcher
Kantonalbank

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Additional Information and Disclaimer

a Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.

Lonza Contact Details

Dirk Oehlers, Head Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications

Lonza Group Ltd

Tel +41 61 316 8798

dominik.werner@lonza.com

Constance Ward, Head External Communications

Lonza Group Ltd

Tel +41 61 316 8840

constance.ward@lonza.com


News Release PDF



Provider
 Channel
 Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50